Revenues: $807.34 million
Three-year revenue growth: 551%
Three-year employee growth: 1,049%
A little-known rising star in pharmaceuticals, Sweden’s Meda develops and sells drugs in two dozen European countries. The company’s target markets include cardiology, dermatology, gastroenterology, respiratory illnesses, and pain and inflammation. Now it’s looking to expand its array of “nichebusters” — drugs that target small patient groups. In July, Meda entered the U.S. market by acquiring MedPointe, a New Jersey-based pharma that makes drugs for neurological and respiratory illnesses.